Spur Therapeutics today announced that it will share updated clinical data from its Phase 1/2 GALILEO-1 and GALILEO-2 trials of avigbagene parvec (FLT201), its Phase 3 gene therapy candidate for Type ...

Charlie Smith. Poster exhibit. Case of Fetal Immature Trauma. The Southern Radiological Conference, Marriott's Grand Hotel, Resort and Spa, Point Clear, Alabama, January 25-27, 2013. Charlie Smith.

Company will provide an overview of the pritelivir clinical development program in two oral presentations including a comprehensive Phase 2 data overview Updated safety and pharmacokinetic results of ...

Azafaros will host a satellite symposium entitled "The value of conducting an 18-month placebo-controlled study in Rare Diseases: GM1, GM2 and NPC; the NAVIGATE experience" on February 3 at 17:45 PT, ...

TScan Therapeutics announced an accepted abstract for poster presentation at ASGCT's annual meeting on TCR-engineered therapies for cancer. TScan Therapeutics, Inc., a clinical-stage biotechnology ...

SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for ...

‒ Poster for GP2 Phase IIb clinical trial final efficacy analysis was presented during the 2020 San Antonio Breast Cancer Symposium (SABCS) today ‒ Phase IIb clinical trial was a prospective, ...

Poster presentations are used to disseminate new knowledge at scientific conferences and meetings and to provide opportunities for liaison within the scientific community. The factors that influence ...

Two-year follow up of FLT201 AAV gene therapy in adults with Type 1 Gaucher Disease: Results from GALILEO-1 and GALILEO-2 Session: Clinical Applications Date & Time: Thursday, February 5, 9:30 a.m.